Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 25,190 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PRE Clear all

Conditions: Portal Hypertension, Liver Fibroses
Interventions: Ultrasound; Diagnostic Test
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 79 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hematologic Malignancies
Interventions: ceritinib; Drug
Lead sponsor: Anne Beaven, MD; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Chronic Hepatitis C
Interventions: Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Placebo; Drug · Other
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 36
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 28 more

Conditions: Nicotine Dependence, Cigarettes
Interventions: AI-enhanced smartphone app, AI-enhanced smartphone app, but with delayed access; Behavioral
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 14 Years to 20 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Asthma
Interventions: Benralizumab; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 12
States / cities: Fountain Valley, California • Walnut Creek, California • Celebration, Florida + 9 more

Conditions: Core Muscle Activation
Interventions: Pelvic Neutral Positioning; Other
Lead sponsor: Dominican University New York; Other
Eligibility: 18 Years to 25 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Jamaica, New York

Conditions: Actinic Keratosis
Interventions: Inggenol Mebutate 0.015%; Drug
Lead sponsor: Goldman, Butterwick, Fitzpatrick and Groff; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Diego, California

Conditions: Health, Recreational Activities, Muscle Protein Synthetic Response to Protein, Muscle Protein Synthesis
Interventions: Resistance Exercise, Isolated Mixture, Rice and Beans; Behavioral · Dietary Supplement · Other
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 20 Years to 35 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Surgery, Geriatric Assessment, Health Services Research, Implementation Science
Interventions: Implementation Package for CGA, Routine Clinical Care; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Cerebral Palsy
Interventions: Virtual Reality Exergaming; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 13 Years to 24 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Parkinson Disease
Interventions: Ioflupane I 123; Drug
Lead sponsor: Julie Gurwell; Other
Eligibility: 40 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Secondary Malignant Neoplasm of Brain and Cerebral Meninges
Interventions: 18F-fluciclovine, PET/CT of the brain; Drug · Device
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent ALK-Positive Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Intravascular Large B-Cell Lymphoma, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory ALK-Positive Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Intravascular Large B-Cell Lymphoma, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography, Golcadomide, Leukapheresis, Positron Emission Tomography, Rituximab; Procedure · Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more

Conditions: Overweight and Obesity
Interventions: MM-based MI, healthy education; Behavioral · Other
Lead sponsor: Michigan State University; Other
Eligibility: 3 Years to 11 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: East Lansing, Michigan

Conditions: HIV Medication Adherence
Interventions: Adherence Readiness Program; Behavioral
Lead sponsor: RAND; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 3
States / cities: Long Beach, California • Los Angeles, California

Conditions: Muscle Strength, Botulinum Toxins, Type A
Interventions: Botulinum Toxin, Type A, Saline; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 54 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Loma Linda, California

Conditions: Hypoglycemia, Evidence of Previous Gastric Surgery
Interventions: Pramlintide; Drug
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 21 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pancreatic Cancer
Interventions: Questionnaires, Blood Draws, Pedometer; Behavioral · Procedure · Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: COVID-19, SARS-CoV2 Infection
Interventions: Polyvinylalcohol strip [diagnostic]; Device
Lead sponsor: Colorado School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 3,300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 2 more

Conditions: Essential Thrombocythemia
Interventions: Ropeginterferon alfa-2b, Anagrelide; Biological · Drug
Lead sponsor: PharmaEssentia; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 4
States / cities: Scottsdale, Arizona • St Louis, Missouri • Houston, Texas + 1 more

Conditions: Oncology
Interventions: Sym013; Drug
Lead sponsor: Symphogen A/S; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Nashville, Tennessee • San Antonio, Texas

Conditions: Obesity
Interventions: Sitagliptin, Pegvisomant, Placebo, L-NMMA, Exendin 9-39; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Leptomeningeal Metastases
Interventions: Involved-field Photon Radiation Therapy, Proton Craniospinal Irradiation (CSI), Neurocognitive Assessment, MDASI-BT and MDASI-SP; Radiation · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 99 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Post-traumatic Stress Disorder, Moral Injury, Traumatic Loss
Interventions: Adaptive Disclosure for Moral Injury and Loss, Present Centered Therapy; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 5
States / cities: San Diego, California • San Francisco, California • Boston, Massachusetts + 2 more

Search by objective public record fields.

Impact of Transjugular Intrahepatic Portosystemic Shunts on Liver Stiffness

Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies

Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C

AI-Enhanced App-based Intervention for Adolescent E-cigarette Cessation

Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home

Core Muscle Activation With Pelvic Neutral Positioning in Division I Soccer Athletes

Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015%

Improving the Anabolic Action of Plant-based Foods Using Complementary Proteins

Implementation Pilot of Preoperative CGA Before Major Surgery

Telehealth Virtual Reality Gaming on Cardiometabolic Health Among Youth With Cerebral Palsy

Idiopathic Parkinson's Progression and Dopamine Transporter SPECT

18F-Fluciclovine PET to Distinguish Tumor Progression From Radiation Necrosis

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

The Feasibility and Preliminary Efficacy of the Mindful-Healthy Family Intervention With Rural Families

Supporting Treatment Adherence Readiness Through Training (START)

Assessment of the Effect of Botulinum Toxin in Extensor Digitorum Brevis Via Strain Gauge and Nerve Conduction Studies

Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery

Identifying the Role of Symptom Outcomes and Biomarkers in Survival in Patients With Metastatic Pancreatic Cancer

Asymptomatic and Pre-symptomatic Transmission of SARS-CoV-2 in a Community Congregant Setting

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies

Effect of DPP4 Inhibition on Growth Hormone Secretion

Proton Craniospinal Radiation Therapy vs. Partial Photon Radiation Therapy for Leptomeningeal Metastasis From Solid Tumors

Psychosocial Rehabilitation After Moral Injury and Loss With Adaptive Disclosure